Comparing high-resolution and pQCT scans to view bone and muscle structure
Official title: Comparison of Bone Microarchitecture Analysed by High Resolution Peripheral Microscanner (HR-pQCT) and Peripheral Microscanner (pQCT) in Pathologies With Bone Loss and/or Muscle Loss
Run by Centre Hospitalier Universitaire de Saint Etienne · NCT06541548 · Data updated 2026-11-12
This study will try high-resolution CT (HR-pQCT), pQCT, and DXA scans to see if they reveal bone and muscle microarchitecture changes in adults at risk of osteoporosis or muscle loss.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne Academic / other |
| Locations | 1 site (Saint-Etienne) |
| Status | Recruiting |
| Started | February 2, 2026 |
| Main results expected | May 2035 |
| Study ends | May 2035 |
| Registry record updated | March 3, 2026 |
| Trial ID | NCT06541548 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults treated at CHU Saint-Etienne with osteoporosis risk or bone fragility and associated conditions listed in the protocol (inflammatory joint disease, chronic kidney disease, specified endocrinopathies, sarcopenia, obesity, anorexia, constitutional thinness, or Parkinson's disease) as well as eligible control participants with recent acute spinal/radicular pain meeting the control criteria.
✕Probably not a fit
Patients who do not consent, who are taking long-term medications known to induce bone loss (where exclusions apply), or who cannot undergo the imaging procedures are unlikely to receive benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants with osteoporosis risk or related conditions (for example rheumatoid arthritis, spondyloarthritis, chronic kidney disease, endocrinopathies, sarcopenia, obesity, anorexia, constitutional thinness, or Parkinson's disease) and a control group will undergo imaging with HR-pQCT (XtremeCT), pQCT (XCT 3000) and DXA. The study compares cortical porosity, trabecular volume and other microarchitectural measures between pathological groups and age-matched controls to distinguish disease-related changes from normal aging. Imaging data will be collected at a single center (CHU Saint-Etienne) and analyzed to characterize differences across conditions. Results aim to clarify which imaging modality best detects microstructural changes that relate to bone fragility.
Why it matters
Potential benefit: If successful, the study could improve identification of patients at higher fracture risk and guide more targeted prevention or treatment.
How similar studies have gone: Previous research has shown HR-pQCT can reveal microarchitectural bone changes that DXA misses, but head-to-head comparisons across the wide set of pathologies included here remain relatively limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: For the patients: Women or men treated at the Saint-Etienne University Hospital and presenting an osteoporotic risk with one of the following associated pathologies: * Osteoporosis defined by: History of a documented brittle bone fracture * Bone fragility: Patient with indication for bone densitometry but no history of fracture * Inflammatory joint disease: * Rheumatoid arthritis * Spondyloarthritis * Chronic kidney disease * Endocrinopathies: * Primary hyperparathyroidism * Constitutional thinness * Anorexia nervosa * Obesity (BMI \>30) * Sarcopenia * Neuropathies - Parkinson's disease For the controls: Acute episode of spinal or radiculalgia (less than one month old) with corticosteroid treatment of less than 1 month Signature of written consent Exclusion Criteria: * No sign written consent For the controls: * Medications inducing bone loss: * anti-aromasin or GnRH agonist for at least 6 months, * corticosteroids (dose ≥ 5 mg/d for 6 months) * anti-epileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, valproic acid for at least 6 months) * History of fracture due to bone fragility * Taking bone-targeting medication (biphosphonate, teriparatide, strontium ranelate)
Where it's running
-
Chu Saint Etienne
Saint-Etienne, France Recruiting
Study contacts
- Principal investigator: Hubert MAROTTE, PhD — Centre Hospitalier Universitaire de Saint Etienne
- Study coordinator: Hubert MAROTTE, PhD
- Email: hubert.marotte@chu-st-etienne.fr
- Phone: (0)477127643
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
All-on-6 upper jaw implants placed with stackable guided surgery and immediate loading
This study will test whether a fully digital stackable guided surgery workflow with immediate loading works well for adults needing full-arch upper jaw (All-on-6) implants.
-
Guided Equator overdentures for the lower jaw
This project tests whether fully guided computer-assisted implant placement with Equator attachments gives reliable implant survival and less bone loss for adults with a completely edentulous lower jaw.
-
Weekly everolimus and resistance training to boost bone health in postmenopausal women
This project will see if a weekly everolimus pill, resistance (strength) training, or both can improve bone formation and muscle function in postmenopausal women aged 60–75.
-
How three prosthetic methods affect bone levels around dental implants
This trial will test whether three different prosthetic approaches for posterior dental implants change marginal bone levels around the implant over one year in adults eligible for Lance implants.
-
Mandibular overdentures held by four Locator attachments versus a four-implant bar
This study tests whether mandibular overdentures retained by four Locator attachments or by a four-implant bar better preserve jaw bone in people who have been fully toothless for at least a year.
-
Evaluation of AdvanCore Bone Graft for Bone Healing
This study is testing if the AdvanCore bone graft can help adults with serious bone defects heal better over a year.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.